The Medical Letter on Drugs and Therapeutics
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 11/9/11: In the clinical studies section, the overall incidence of endoscopic gastroduodenal ulcers should have been 11% with Duexis and 21.9% with ibuprofen alone and, in low dose aspirin users, 12.8% with Duexis and 32.8% with ibuprofen alone.

The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.1

NSAIDs AND GI TOXICITY — NSAIDs inhibit synthesis of prostaglandins, which have a protective effect on the gastric mucosa. They are more likely to cause gastric than duodenal ulcers.2 Up to 40% of chronic NSAID users report having dyspepsia, and 1-2% develop life-threatening consequences of peptic ulcer ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
Article code: 1376a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian